Abstract:Background: Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC). In the intestine, it is transformed into SN-38 by gut microbial enzymes, which is responsible for its toxicity during excretion. Objective: Our study highlights the impact of Irinotecan on gut microbiota composition and the role of probiotics in limiting Irinotecan-associated diarrhea and suppressing gut bacterial β-glucuronidase enzymes. Material and methods: To investigate the effect of Irinotecan on the gut microbiota composition, we applied 16S rRNA gene sequencing in three groups of stool samples from healthy individuals, colon cancer, and Irinotecan treated patients (n = 5/group). Furthermore, three Lactobacillus spp.; Lactiplantibacillus plantarum (L. plantarum), Lactobacillus acidophilus (L. acidophilus), Lacticaseibacillus rhamnosus (L. rhamnosus) were used in a single and mixed form to in-vitro explore the effect of probiotics on the expression of β-glucuronidase gene from E. coli. Also, probiotics were introduced in single and mixed forms in groups of mice before the administration of Irinotecan, and their protective effects were explored by assessing the level of reactive oxidative species (ROS) as well as studying the concomitant intestinal inflammation and apoptosis. Results: The gut microbiota was disturbed in individuals with colon cancer and after Irinotecan treatment. In the healthy group, Firmicutes were more abundant than Bacteriodetes, which was the opposite in the case of colon-cancer or Irinotecan treated groups. Actinobacteria and Verrucomicrobia were markedly present within the healthy group, while Cyanobacteria were noted in colon-cancer and the Irinotecan-treated groups. Enterobacteriaceae and genus Dialister were more abundant in the colon-cancer group than in other groups. The abundance of Veillonella, Clostridium, Butryicicoccus, and Prevotella were increased in Irinotecan-treated groups compared to other groups. Using Lactobacillus spp. mixture in mice models significantly relieved Irinotecan-induced diarrhea through the reduction of both β-glucuronidase expression and ROS, in addition to guarding gut epithelium against microbial dysbiosis and proliferative crypt injury. Conclusions: Irinotecan-based chemotherapy altered intestinal microbiota. The gut microbiota participates greatly in determining both the efficacy and toxicity of chemotherapies, of which the toxicity of Irinotecan is caused by the bacterial ß-glucuronidase enzymes. The gut microbiota can now be aimed and modulated to promote efficacy and decrease the toxicity of chemotherapeutics. The used probiotic regimen in this study lowered mucositis, oxidative stress, cellular inflammation, and apoptotic cascade induction of Irinotecan.

Intestinal Toxicity of Irinotecan and Its Clinical Prevention

Mechanisms and Emerging Strategies for Irinotecan-Induced Diarrhea

Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis

Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea

Herbal Medicines for Irinotecan-Induced Diarrhea

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity

Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats

Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: the Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea.

Research Progress on Irinotecan Induced Metabolic Dysregulation in Microbiota-Gut-liver Axis and Chinese Materia Medica Intervention

Control of irinotecan-induced diarrhea by octreotide after loperamide failure

Drug-Drug Interactions and Disease Status Are Associated with Irinotecan-Induced Hepatotoxicity: A Cross-Sectional Study in Shanghai.

Effect of ShengJiangXieXinTang on the intestinal mucosal immune barrier of rats receiving Irinotecan

Efifcacy and Predictive Molecule Markers Associated Toxicity of Irinotecan for Colorectal Cancer

Targeted inhibition of Gus-expressing Enterococcus faecalis to promote intestinal stem cell and epithelial renovation contributes to the relief of irinotecan chemotoxicity by dehydrodiisoeugenol

Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer

[Polymorphisms of UGT1A Gene and Irinotecan Toxicity in Chinese Colorectal Cancer Patients].

Fecal SN-38 Content as a Surrogate Predictor of Intestinal SN-38 Exposure and Associated Irinotecan-induced Severe Delayed-Onset Diarrhea by a Novel Use of the Spectrofluorimetric Method

Amplication Influence of Deoxyschizandrin Towards Adverse Effect of Glioma Therapeutic Drug Irinotecan

The effective combination therapies with irinotecan for colorectal cancer

Roles of Breast Cancer Resistance Protein and Organic Anion Transporting Polypeptide 2B1 in Gastrointestinal Toxicity Induced by SN-38 under Inflammatory Conditions

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial Β-Glucuronidase